Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$58 Mln
P/E Ratio
--
P/B Ratio
0.46
Industry P/E
--
Debt to Equity
0.06
ROE
-0.33 %
ROCE
-31.36 %
Div. Yield
0 %
Book Value
2.62
EPS
-1.03
CFO
$-215.61 Mln
EBITDA
$-240.61 Mln
Net Profit
$-229.98 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ikena Oncology (IKNA)
| -20.73 | -1.52 | -12.16 | 0.00 | -30.30 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Ikena Oncology (IKNA)
| -16.63 | -25.94 | -78.79 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,315.11 | 21.27 | 23.13 | |
| 306.35 | 8,705.27 | 22.77 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive... complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Read more
President, CEO & Director
Dr. Mark Manfredi Ph.D.
President, CEO & Director
Dr. Mark Manfredi Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ikena Oncology Inc (IKNA) stood at $ 142 Mln as on 31-Dec-24
The share price of Ikena Oncology Inc (IKNA) is $1.30 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Ikena Oncology Inc (IKNA) has given a return of -30.3% in the last 3 years.
Ikena Oncology Inc (IKNA) has a market capitalisation of $ 58 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Ikena Oncology Inc (IKNA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ikena Oncology Inc (IKNA) and enter the required number of quantities and click on buy to purchase the shares of Ikena Oncology Inc (IKNA).
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
The CEO & director of Dr. Mark Manfredi Ph.D.. is Ikena Oncology Inc (IKNA), and CFO & Sr. VP is Dr. Mark Manfredi Ph.D..
There is no promoter pledging in Ikena Oncology Inc (IKNA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Ikena Oncology Inc. (IKNA) | Ratios |
|---|---|
|
Return on equity(%)
|
-33.3
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ikena Oncology Inc (IKNA) was $0 Mln.
$0.03
(
